Teva
Teva’s Ajovy significantly reduces migraine in children and adolescents
January 12, 2026Research and Development Neurology, Teva, ajovy, migraine
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children and adolescents with episodic migraine …
Teva announces positive results from trial of AJOVY for migraine
December 5, 2025Research and Development Neurology, Teva, migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its treatment for chronic (CM) and …
Sanofi and Teva partner for development of inflammatory bowel disease treatment
October 4, 2023Medical Communications Crohn’s disease, Gastrointestinal tract, Sanofi, Teva, bowel disease, ulcerative colitis
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation of TEV’574, a treatment for …
Teva’s cancer drug Bendeka protected from generics until 2031, judge rules
April 30, 2020Business Services Bendeka, Teva, Teva and Eagle
A US federal judge has ruled that generic versions of the cancer treatment Bendeka infringe on four separate patents, and …
Teva’s Ajovy becomes first drug of its kind available on NHS for prevention of chronic migraine
March 12, 2020Sales and Marketing NICE, Teva, ajovy, migraine, pharma
NICE has announced the authorisation of Teva’s anti-CGRP drug Ajovy (fremanezumab) for the prevention of chronic migraine in adult patients …
Teva’s Austedo fails in two paediatric Tourette’s syndrome trials
February 21, 2020Medical Communications, Research and Development Austedo, Teva, pharma, tourette's
Israeli firm Teva has shared disappointing results for its vesicular monoamine transporter 2 (VMAT2) Austedo (deutetrabenazine) after it failed to …
FDA approves Teva’s Ajovy autoinjector for treatment of migraine
January 29, 2020Research and Development, Sales and Marketing FDA, Teva, ajovy, migraine, pharma
Israeli pharma firm Teva has revealed that the FDA has chosen to award approval to its autoinjector device for the …
Top Ten most popular articles on Pharmafile.com this week
January 17, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Big Pharma, European Commission, FDA, Pakistan, Sanofi, Teva
Pakistan is cracking down on corruption and has registered cases against 200 pharmaceutical companies, while in the US the FDA …
Teva to settle bribery lawsuit with $54 million payout
January 7, 2020Manufacturing and Production, Sales and Marketing Teva, bribery, pharma
Israeli drug firm Teva has agreed to settle an ongoing lawsuit levying allegations of the company’s bribery of doctors, it …
Four perspectives from life sciences companies on multichannel engagement
August 23, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Biogen, GSK, Lifesciences, Teva, healthcare, pharma
By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in …
Teva launch generic version of EpiPen for children
August 21, 2019Research and Development Mylan, Teva, allergies, children, epipen, pharma
A generic version of Mylan’s EpiPen, manufactured by Teva, is now available for children weighing between 15kg and 30kg in …
Teva recall heart drug after carcinogen found in API
June 14, 2019Medical Communications API, Contamination, NMDA, Teva, carcinogen, pharma, recall
Teva Pharmaceuticals has expanded its recall of losartan potassium tablets after detecting a possible carcinogen in an active pharmaceutical ingredient …
Top Ten most popular articles on Pharmafile.com this week!
May 17, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics
Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …
Teva terminates Ajovy at Phase 3 in episodic cluster headache
April 24, 2019Research and Development Teva, ajovy, headache, pharma
Israeli pharmaceutical firm Teva has announced its intention to terminate further development of its calcitonin gene-related peptide (CGRP) inhibitor Ajovy …
Teva’s Ajovy injection secures EU approval for the prevention of migraine
April 2, 2019Manufacturing and Production, Sales and Marketing EU, Europe, Teva, ajovy, migraine, pharma
Teva has announced that its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) has been awarded marketing authorisation by the European …
